Exploring top five trends shaping the future of oncology clinical trials with Ravi Karra
With so much innovation taking place in the oncology trial landscape, fueled by pharmaceutical and biotechnology companies it’s important to know all that is going on–and what’s to come in the future of oncology trials.
In the July 2024, Pharmaphorum Oncology Deep Dive Advanced Clinical’s VP of oncology, Ravi Karra, explores the top five trends shaping the future of oncology clinical trials.
- innovative trial designs,
- transformations in early phase development,
- rise of new drug classes,
- groundbreaking imaging techniques,
- optimizing existing cancer treatments to suit patient profiles.
Read the full article on the Pharmaphorum website.
Ravi Karra is the Vice President of Oncology at Advanced Clinical. Karra has worked closely with bodies such as the FDA and EMA and has been involved in innovative trial designs that use translational research data, including molecular and imaging biomarkers. He is also a Board Member of OncoDaily.
He specializes in brain tumors, melanoma and head and neck cancer, has an extensive background in developing strategies for designing and running clinical trials in several tumor types, including rare cancers like glioblastoma, salivary gland, thyroid and uveal melanoma.